Cluster page — primary care pharmacy
Clinical pharmacist ROI & impact
Benchmarks
Typical impact per WTE clinical pharmacist per year
How ROI is built
The five components of clinical pharmacist value
1. Direct reimbursement. Under ARRS the role's salary, on-costs and indemnity are fully reimbursed within the funding envelope. The PCN's net cash cost is zero for a compliantly claimed post.
2. Released GP capacity. Pharmacists absorb repeat prescribing administration, discharge reconciliation, titration appointments and medicines queries — work that would otherwise sit on GP appointment lists. Most practices measure 4–6 hours per clinic session.
3. Prescribing cost reduction. Structured deprescribing in frailty and polypharmacy cohorts reduces items per patient by 8–12%; biosimilar pathways and anticoagulation switches add further savings at PCN scale.
4. DES achievement protection. The PCN's SMR delivery, EHCH and Anticipatory Care DES payments depend on clinical pharmacist capacity. A vacancy is a direct risk to PCN income.
5. Prescribing safety and avoided harm. Closing MHRA Drug Safety Update alerts, monitoring DMARDs and lithium to NICE intervals, and reconciling discharges within 7 days reduces medication-related admissions — measurable at ICB level via SUS data and consistently observed in mature programmes.
Frequently asked questions
ROI — FAQs
What is the typical return on investment for a PCN clinical pharmacist?+
On the ARRS-funded model the role is fully reimbursed, so direct cash ROI is 100% — the PCN's return comes via released GP capacity (4–6 hours per clinic session), prescribing cost reduction (typically 2–4% of the practice drug budget after a frailty SMR programme), and DES achievement payments that would otherwise be at risk.
How is GP time released calculated?+
Pharmacists absorb medication queries, discharge reconciliation, prescribing safety alert work, titration and SMR clinics that would otherwise sit on GP appointment lists. Practices that measure this consistently report 4–6 hours of GP appointment time released per pharmacist clinic session.
What prescribing cost savings can a clinical pharmacist deliver?+
After a structured frailty and polypharmacy SMR programme, BCS sees typical reductions of 8–12% in prescribing items per patient reviewed, which translates to 2–4% of practice-level drug spend. Bigger savings come from anticoagulation switches, biosimilar pathways and low-value medicines deprescribing.
How should impact be reported to the ICB?+
Quarterly: SMRs delivered against DES target, prescribing safety alert closure, high-risk drug monitoring compliance, care home review coverage, prescribing cost trend versus ICB peer median, patient experience sampling. BCS provides this report as standard for managed-service PCNs.
Talk to our Service Development team
30-minute discovery call. We'll show you how BCS maps to your PCN's specific priorities.